drug · small molecule
selinexor
Marketedupdated 5mo agoby $KPTI Karyopharm Therapeutics Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 29 investigational indications.
indications
investigational
DLBCL
targets
Exportin-1
all catalysts(7)
approval · 7
Jul 3, 2019
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Jun 22, 2020
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Dec 18, 2020
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Mar 28, 2022
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Jul 15, 2022
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Mar 10, 2025
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Sep 26, 2025
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Trials studying selinexor
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase2Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- phase3Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- phase1Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- phase3Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- phase3Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 22, 2027
261 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (66)
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035method-of-use (U-2855)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-2584)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-3018)US 11787771
- Jul 26, 2032method-of-use (U-2584)US 11787771
- Jul 26, 2032method-of-use (U-3018)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 12291508
- Jul 26, 2032method-of-use (U-2855)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-3018)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-3018)US 9079865
- Jul 26, 2032method-of-use (U-2855)US 9079865
- Jul 26, 2032method-of-use (U-3018)US 9079865
- Jul 26, 2032method-of-use (U-2584)US 9079865
- Jul 26, 2032method-of-use (U-2584)US 9079865
- Jul 26, 2032method-of-use (U-2855)US 9079865
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
FDA exclusivities (17)
- Dec 18, 2027ODE*ODE*1.2y
- Dec 18, 2027ODE*ODE*1.2y
- Dec 18, 2027ODE*ODE*1.2y
- Dec 18, 2027ODE-346Orphan Drug (7y)1.2y
- Dec 18, 2027ODE*ODE*1.2y
- Dec 18, 2027ODE*ODE*1.2y
- Jun 22, 2027ODE*ODE*261d
- Jun 22, 2027ODE-310Orphan Drug (7y)261d
- Jun 22, 2027ODE*ODE*261d
- Jun 22, 2027ODE*ODE*261d
- Jun 22, 2027ODE*ODE*261d
- Jul 3, 2026ODE-257Orphan Drug (7y)
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
News(2)
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 22d ago
- Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancerKaryopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, c…endpoints · 2mo ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that